Tumor-Informed MRD
● Baseline WES testing
● 50 Patient-specific Variants
● 100,000x Ultra-deep sequencing

Methylation based MRD
● Patented, highly sensitive methylation detection technology
● Profiles over 56,000 to 70,000 methylation variants
● Clinically validated across multiple cancer types, enabling reliable tumor-naive MRD detection.

Epigenomics-Genomics Based MRD
● Epigenomic and genomic profiling analysis enhance detection of clinical/emerging biomarkers and therapeutic insights
● Flexible genomic profiling modules, including BNR's OncoCompass panel series, WGS, and other platforms.

Performance Validations

CanCatch^® Leverages genomic and epigenomic profiling to offer diverse MRD detection Solutions.

* : cfDNA down to 0.01%; Cell lines down to 0.004%

Clinical Trial Studies

MEDAL Study¹: Tumor Informed MRD

● CanCatch^® personalized MRD assay outperforms fixed-panel mutation assays in NSCLC in the MEDAL Study.

● The CanCatch^® assay achieved a high NPV of 95.5% at 720 days and provided a median le=ad time of 299 days to radiological recurrence.

● The TNMB stage, combining landmark ctDNA MRD with TNM, enhanced prognosis prediction.

● Post-relapse ctDNA status aids in guiding subsequent treat ment decisions.

Methylation-based MRD^2,3

● The ELSA-seq technology integrates single-base methylation sequencing, multi-layer noise reduction, and machine learning to detect ctDNA at levels as low as 0.01%.

● An accurate methylation-based ctDNA quantification metric, TMeF, was developed and validated across multiple tumor types.

● In patients with stage I lung adenocarcinoma, ctDNA-positive individuals exhibited significantly inferior recurrence-free survival (RFS) compared to ctDNA-negative patients.

1. Chen et al., 2023, Cancer Cell 41, 1-14, October 9, 2023

2. Liang et al., 2021,Nature Biomedical Engineering 5, 586-599,1 June 15, 2021

3. Internal data.